Project Grant K23HL175237
Award Date
6/15/25
Completion Date
5/31/30
Dollars Obligated
$156K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $844,386 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct research on childhood interstitial lung disease (CHILD). The key objectives are to: 1) Expand gene expression profiling of 300 CHILD lung biopsy samples to define patient subgroups with similar molecular profiles, develop a...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 5-year, $637,526 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Duke University. The grant supports research to investigate how sickle cell disease (SCD) impacts neutrophil activation and function. The project aims to delineate the specific mechanisms by which sickle red blood cells (RBCs) directly induce neutrophil activation in SCD, and examine if these interactions correlate with acute...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), has awarded a $772,400 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Children's Hospital of Philadelphia (CHOP) Research Institute. The grant, titled "Decellularized Cartilage and Progenitor Cells for Laryngotracheal Reconstruction," aims to develop innovative tissue engineering solutions to address severe subglottic stenosis, a life-threatening airway...
This National Heart, Lung, and Blood Institute (NHLBI) Project Grant award (CFDA 93.837 - Cardiovascular Diseases Research) provides $2,654,903 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop a novel platform based on alpha-retroviral vectors for delivering gene therapy payloads, including integrating DNA and CRISPR/Cas9 ribonucleoprotein complexes, into hematopoietic stem cells both ex vivo and in vivo. The goal is to enable simpler, more...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $185,178 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Rhode Island Hospital, a division of Lifespan Corporation, to support the "Postdoctoral Research Training in Child Health Equity" program. This multidisciplinary training program aims to prepare postdoctoral fellows to conduct rigorous, community-engaged research addressing health disparities in pediatric respiratory, cardiovascular/metabolic, and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,829,965.51 to the Children's Research Institute to conduct a randomized, double-blind, placebo-controlled Phase 2 clinical trial of intravenous citrulline for vaso-occlusive crisis in sickle cell disease. The key products or services to be delivered include evaluating whether the administration of intravenous citrulline, in...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $827,753.90 to Bloodworks (doing business as Puget Sound Blood Center and Program) to conduct research on oxidative stress and cysteine modification in sickle cell disease. The research aims to investigate how thiol isomerases, a class of oxidoreductase enzymes, promote vaso-occlusion - a major clinical burden in sickle cell...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $802,500 Cooperative Agreement under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant supports the construction of a multi-scale 3D AI-powered map of genetic factors involved in normal and abnormal childhood lung development, with a focus on Childhood Interstitial Lung Disease (CHILD). The 5-year project leverages advanced techniques like...
The Dana-Farber Cancer Institute, Inc. (DFCI) was awarded a $254,604 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. This 5-year grant will fund research to develop and evaluate a novel, community-based collaborative care model to deliver a resilience-focused intervention for adolescents and young adults (AYAs) with sickle cell disease. The project aims to assess the feasibility and acceptability of the...
This federal Project Grant award, totaling $608,126.00 and awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and validate single-cell biomarkers for predicting clinical outcomes in sickle cell disease (SCD). The grant supports research to: Define the relationship between SCD adverse clinical outcomes and single-cell biochemical and mechanical properties to identify promising biomarkers. Define the...